REFERENCES
- Yoshida M., Furumai R., Nishiyama M., Komatsu Y., Nishino N., Horinouchi S. Histone deacetylase as a new target for cancer chemotherapy. Cancer Chemother. Pharmacol. 2001; 48(Suppl.)S20–S26, [INFOTRIEVE], [CSA]
- Luger K., Mader A W., Richmond R. K., Sargent D. F., Richmond T. J. Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature 1997; 389: 251–260, [INFOTRIEVE], [CSA], [CROSSREF]
- Jenuwein T., Allis C. D. Translating the histone code. Science 2001; 293: 1074–1080, [INFOTRIEVE], [CSA], [CROSSREF]
- Wu J., Grunstein M. 25 years after the nucleosome model: chromatin modifications. Trends Biochem. Sci. 2000; 25: 619–623, [INFOTRIEVE], [CSA], [CROSSREF]
- Bhalla K. N. Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J. Clin. Oncol. 2005; 23: 3971–3993, [INFOTRIEVE], [CSA], [CROSSREF]
- Mai A., Massa S., Rotili D., Cerbara I., Valente S., et al. Histone deacetylation in epigenetics: an attractive target for anticancer therapy. Med. Res. Rev. 2005; 25: 261–309, [INFOTRIEVE], [CSA], [CROSSREF]
- Minucci S., Pelicci P. G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer 2006; 6: 38–51, [INFOTRIEVE], [CSA], [CROSSREF]
- Marks P., Rifkind R., Richon V., Breslow R., Miller T., Kelly W. Histone deacetylases and cancer: Causes and therapies. Nature Reviews 2001; 1: 194–202, [INFOTRIEVE], [CSA], [CROSSREF]
- Turner B. M. Histone acetylation as an epigenetic determinant of long-term transcriptional competence. Cell Mol. Life Sci. 1998; 54: 21–31, [INFOTRIEVE], [CSA], [CROSSREF]
- Weidle U. H., Grossmann A. Inhibition of histone deacetylases: a new strategy to target epigenetic modifications for anticancer treatment. Anticancer Res. 2000; 20: 1471–1485, [INFOTRIEVE], [CSA]
- Marmorstein R. Structure of histone acetyltransferases. J. Mol. Biol. 2001; 311: 433–444, [INFOTRIEVE], [CSA], [CROSSREF]
- Norton V. G., Imai B. S., Yau P., Bradbury E. M. Histone acetylation reduces nucleosome core particle linking number change. Cell 1989; 57: 449–457, [INFOTRIEVE], [CSA], [CROSSREF]
- Shea T. B., Beermann M. L., Nixon R. A. Post-translational modification of alpha-tubulin by acetylation and detyrosination in NB2a/d1 neuroblastoma cells. Brain Res. Dev. Brain Res. 1990; 51: 195–204, [INFOTRIEVE], [CSA], [CROSSREF]
- Hasan S., Hottiger M. O. Histone acetyl transferases: a role in DNA repair and DNA replication. J. Mol. Med. 2002; 80: 463–474, [INFOTRIEVE], [CSA], [CROSSREF]
- Marks P. A., Richon V. M., Miller T., Kelly W. K. Histone deacetylase inhibitors. Adv. Cancer Res. 2004; 91: 137–168, [INFOTRIEVE], [CSA]
- Acharya M. R., Sparreboom A., Venitz J., Figg W. D. Rational development of histone deacetylase inhibitors as anticancer agents: a review. Mol. Pharmacol. 2005; 68: 917–932, [INFOTRIEVE], [CSA], [CROSSREF]
- Dokmanovic M., Marks P. A. Prospects: histone deacetylase inhibitors. J. Cell Biochem. 2005; 96: 293–304, [INFOTRIEVE], [CSA], [CROSSREF]
- Drummond D. C., Noble C. O., Kirpotin D. B., Guo Z., Scott G. K., Benz C. C. Clinical development of histone deacetylase inhibitors as anticancer agents. Annu. Rev. Pharmacol. Toxicol. 2005; 45: 495–528, [INFOTRIEVE], [CSA], [CROSSREF]
- Voelter-Mahlknecht S., Ho A. D., Mahlknecht U. Chromosomal organization and localization of the novel class IV human histone deacetylase 11 gene. Int. J. Mol. Med. 2005; 16: 589–598, [INFOTRIEVE], [CSA]
- Miller T. A., Witter D. J., Belvedere S. Histone deacetylase inhibitors. J. Med. Chem. 2003; 46: 5097–5116, [INFOTRIEVE], [CSA], [CROSSREF]
- Wade P. A., Wolffe A. P. Histone acetyltransferases in control. Curr. Biol. 1997; 7: R82–R84, [INFOTRIEVE], [CSA], [CROSSREF]
- Gray S. G., Ekstrom T. J. The human histone deacetylase family. Exp. Cell Res. 2001; 262: 75–83, [INFOTRIEVE], [CSA], [CROSSREF]
- Glozak M. A., Sengupta N., Zhang X., Seto E. Acetylation and deacetylation of non-histone proteins. Gene 2005; 363: 15–23, [INFOTRIEVE], [CSA], [CROSSREF]
- Deckert J, Struhl K. Histone acetylation at promoters is differentially affected by specific activators and repressors. Mol. Cell Biol. 2001; 21: 2726–2735, [INFOTRIEVE], [CSA], [CROSSREF]
- Kovacs J. J., Murphy P. J., Gaillard S., Zhao X., Wu J. T., Nicchitta C. V., Yoshida M., Toft D. O., Pratt W. B., Yao T. P. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol. Cell 2005; 18: 601–607, [INFOTRIEVE], [CSA], [CROSSREF]
- Giles R. H., Peters D. J., Breuning M. H. Conjunction dysfunction: CBP/p300 in human disease. Trends Genet. 1998; 14: 178–183, [INFOTRIEVE], [CSA], [CROSSREF]
- Rowley J. D., Reshmi S., Sobulo O., Musvee T., Anastasi J., et al. All patients with the T(11;16)(q23;p13.3) that involves MLL and CBP have treatment-related hematologic disorders. Blood 1997; 90: 535–541, [INFOTRIEVE], [CSA]
- Petrij F., Giles R. H., Dauwerse H. G., Saris J. J., Hennekam R. C., et al. Rubinstein-Taybi syndrome caused by mutations in the transcriptional co-activator CBP. Nature 1995; 376: 348–351, [INFOTRIEVE], [CSA], [CROSSREF]
- Iyer N. G., Ozdag H., Caldas C. p300/CBP and cancer. Oncogene 2004; 23: 4225–4231, [INFOTRIEVE], [CSA], [CROSSREF]
- Grignani F., De Matteis S., Nervi C., Tomassoni L., Gelmetti V., et al. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature 1998; 391: 815–818, [INFOTRIEVE], [CSA], [CROSSREF]
- He L. Z., Guidez F., Tribioli C., Peruzzi D., Ruthardt M., Zelent A., Pandolfi P. P. Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL. Nat. Genet. 1998; 18: 126–135, [INFOTRIEVE], [CSA], [CROSSREF]
- Lin R. J., Nagy L., Inoue S., Shao W., Miller W. H., Jr., Evans R. M. Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature 1998; 391: 811–814, [INFOTRIEVE], [CSA], [CROSSREF]
- Dhordain P., Lin R. J., Quief S., Lantoine D., Kerckaert J. P., Evans R. M., Albagli O. The LAZ3(BCL-6) oncoprotein recruits a SMRT/mSIN3A/histone deacetylase containing complex to mediate transcriptional repression. Nucleic Acids Res. 1998; 26: 4645–4651, [INFOTRIEVE], [CSA], [CROSSREF]
- Wang J., Saunthararajah Y., Redner R. L., Liu J. M. Inhibitors of histone deacetylase relieve ETO-mediated repression and induce differentiation of AML1-ETO leukemia cells. Cancer Res. 1999; 59: 2766–2769, [INFOTRIEVE], [CSA]
- Wang J., Hoshino T., Redner R. L., Kajigaya S., Liu J. M. ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex. Proc. Natl. Acad. Sci. USA 1998; 95: 10860–10865, [INFOTRIEVE], [CSA], [CROSSREF]
- Yarden Y., Sliwkowski M. X. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. 2001; 2: 127–137, [INFOTRIEVE], [CSA], [CROSSREF]
- Siddique H., Zou J. P., Rao V. N., Reddy E. S. The BRCA2 is a histone acetyltransferase. Oncogene 1998; 16: 2283–2285, [INFOTRIEVE], [CSA], [CROSSREF]
- Vigushin D. M., Coombes R. C. Targeted histone deacetylase inhibition for cancer therapy. Curr. Cancer Drug Targets 2004; 4: 205–218, [INFOTRIEVE], [CSA], [CROSSREF]
- Qian D. Z., Wang X., Kachhap S. K., Kato Y., Wei Y., Zhang L., Atadja P., Pili R. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584. Cancer Res. 2004; 64: 6626–6634, [INFOTRIEVE], [CSA], [CROSSREF]
- Finnin M. S., Donigian J. R., Cohen A., Richon V. M., Rifkind R. A., et al. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 1999; 401: 188–193, [INFOTRIEVE], [CSA], [CROSSREF]
- Johnstone R. W. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat. Rev. Drug Discov. 2002; 1: 287–299, [INFOTRIEVE], [CSA], [CROSSREF]
- Nakajima H., Kim Y. B., Terano H., Yoshida M., Horinouchi S. FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Exp. Cell Res. 1998; 241: 126–133, [INFOTRIEVE], [CSA], [CROSSREF]
- Kim M. S., Kwon H. J., Lee Y. M., Baek J. H., Jang J. E., et al. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat. Med. 2001; 7: 437–443, [INFOTRIEVE], [CSA], [CROSSREF]
- Yu X., Guo Z. S., Marcu M. G., Neckers L., Nguyen D. M., Chen G. A., Schrump D. S. Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J. Natl. Cancer Inst. 2002; 94: 504–513, [INFOTRIEVE], [CSA]
- Nimmanapalli R., Fuino L., Bali P., Gasparetto M., et al. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells. Cancer Res. 2003; 63: 5126–5135, [INFOTRIEVE], [CSA]
- Bali P., George P., Cohen P., Tao J., Guo F., et al. Superior activity of the combination of histone deacetylase inhibitor LAQ824 and the FLT-3 kinase inhibitor PKC412 against human acute myelogenous leukemia cells with mutant FLT-3. Clin. Cancer Res. 2004; 10: 4991–4997, [INFOTRIEVE], [CSA], [CROSSREF]
- Nebbioso A., Clarke N., Voltz E., Germain E., Ambrosino C., et al. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat. Med. 2005; 11: 77–84, [INFOTRIEVE], [CSA], [CROSSREF]
- Ruefli A. A., Ausserlechner M. J., Bernhard D., Sutton V. R., Tainton K. M., et al. The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl. Acad. Sci. USA 2001; 98: 10833–10838, [INFOTRIEVE], [CSA], [CROSSREF]
- Marks P. A., Jiang X. Histone deacetylase inhibitors in programmed cell death and cancer therapy. Cell Cycle 2005; 4: 549–551, [INFOTRIEVE], [CSA]
- Ungerstedt J. S., Sowa Y., Xu W. S., Shao Y., Dokmanovic M., et al. Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc. Natl. Acad. Sci. USA 2005; 102: 673–678, [INFOTRIEVE], [CSA], [CROSSREF]
- Jabs T. Reactive oxygen intermediates as mediators of programmed cell death in plants and animals. Biochem. Pharmacol. 1999; 57: 231–245, [INFOTRIEVE], [CSA]
- Piekarz R. L., Robey R., Sandor V., Bakke S., Wilson W. H., et al. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood 2001; 98: 2865–2868, [INFOTRIEVE], [CSA]
- Kelly W. K., Richon V. M., O'Connor O., Curley T., MacGregor-Curtelli B., et al. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin. Cancer Res. 2003; 9: 3578–3588, [INFOTRIEVE], [CSA]
- Byrd J. C., Marcucci G., Parthun M. R., Xiao J. J., Klisovic R. B., et al. A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood 2005; 105: 959–967, [INFOTRIEVE], [CSA], [CROSSREF]
- Butler L. M., Zhou X., Xu W. S., Scher H. I., Rifkind R. A., Marks P. A., Richon V. M. The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proc Natl. Acad. Sci. USA 2002; 99: 11700–11705, [INFOTRIEVE], [CSA], [CROSSREF]
- Van Lint C., Emiliani S., Verdin E. The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Expr. 1996; 5: 245–253, [INFOTRIEVE], [CSA]
- Glaser K. B., Staver M. J., Waring J. F., Stender J., Ulrich R. G., Davidsen S. K. Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol. Cancer Ther. 2003; 2: 151–163, [INFOTRIEVE], [CSA]
- Mitsiades C. S., Mitsiades N. S., McMullan C. J., Poulaki V., Shringarpure R., et al. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl. Acad. Sci. USA 2004; 101: 540–545, [INFOTRIEVE], [CSA], [CROSSREF]
- Romanski A., Bacic B., Bug G., Pfeifer H., et al. Use of a novel histone deacetylase inhibitor to induce apoptosis in cell lines of acute lymphoblastic leukemia. Haematologica 2004; 89: 419–426, [INFOTRIEVE], [CSA]
- Weisberg E., Catley L., Kujawa J., Atadja P., Remiszewski S., et al. Histone deacetylase inhibitor NVP-LAQ824 has significant activity against myeloid leukemia cells in vitro and in vivo. Leukemia 2004; 18: 1951–1963, [INFOTRIEVE], [CSA], [CROSSREF]
- He L. Z., Tolentino T., Grayson P., Zhong S., Warrell R. P., Jr., et al. Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. J. Clin. Invest 2001; 108: 1321–1330, [INFOTRIEVE], [CSA], [CROSSREF]
- Ueda H., Nakajima H., Hori Y., Fujita T., Nishimura M., Goto T., Okuhara M. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity. J. Antibiot. (Tokyo) 1994; 47: 301–310, [CSA]
- Ueda H., Manda T., Matsumoto S., Mukumoto S., Nishigaki F., Kawamura I., Shimomura K. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. III. Antitumor activities on experimental tumors in mice. J. Antibiot. (Tokyo) 1994; 47: 315–323, [CSA]
- Ito T., Ouchida M., Morimoto Y., Yoshida A., Jitsumori Y., et al. Significant growth suppression of synovial sarcomas by the histone deacetylase inhibitor FK228 in vitro and in vivo. Cancer Lett. 2005; 224: 311–319, [INFOTRIEVE], [CSA], [CROSSREF]
- Eyupoglu I. Y., Hahnen E., Buslei R., Siebzehnrubl F. A., Savaskan N. E., et al. Suberoylanilide hydroxamic acid (SAHA) has potent anti-glioma properties in vitro, ex vivo and in vivo. J. Neurochem. 2005; 93: 992–999, [INFOTRIEVE], [CSA], [CROSSREF]
- Xiao J. J., Foraker A. B., Swaan P. W., Liu S., Huang Y., et al. Efflux of depsipeptide FK228 (FR901228, NSC-630176) is mediated by P-glycoprotein and multidrug resistance-associated protein 1. J. Pharmacol. Exp. Ther. 2005; 313: 268–276, [INFOTRIEVE], [CSA], [CROSSREF]
- Saito A., Yamashita T., Mariko Y., Nosaka Y., Tsuchiya K., et al. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc Natl. Acad. Sci. USA 1999; 96: 4592–4597, [INFOTRIEVE], [CSA], [CROSSREF]
- Hockly E., Richon V. M., Woodman B., Smith D. L., Zhou X., et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc Natl. Acad. Sci. USA 2003; 100: 2041–2046, [INFOTRIEVE], [CSA], [CROSSREF]
- Catley L., Weisberg E., Tai Y. T., Atadja P., Remiszewski S., et al. NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood 2003; 102: 2615–2622, [INFOTRIEVE], [CSA], [CROSSREF]
- Glick R. D., Swendeman S. L., Coffey D. C., Rifkind R. A., Marks P. A., Richon V. M., La Quaglia M. P. Hybrid polar histone deacetylase inhibitor induces apoptosis and CD95/CD95 ligand expression in human neuroblastoma. Cancer Res. 1999; 59: 4392–4399, [INFOTRIEVE], [CSA]
- Jaboin J., Wild J., Hamidi H., Khanna C., Kim C. J., et al. MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors. Cancer Res. 2002; 62: 6108–6115, [INFOTRIEVE], [CSA]
- Graham C., Tucker C., Creech J., Favours E., Billups C. A., et al. Evaluation of the antitumor efficacy, pharmacokinetics, and pharmacodynamics of the histone deacetylase inhibitor depsipeptide in childhood cancer models in vivo. Clin. Cancer Res. 2006; 12: 223–234, [INFOTRIEVE], [CSA], [CROSSREF]
- Sandor V., Bakke S., Robey R. W., Kang M. H., Blagosklonny M. V., et al. Phase I. trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res. 2002; 8: 718–728, [INFOTRIEVE], [CSA]
- Marshall J. L., Rizvi N., Kauh J., Dahut W., Figuera M., et al. A phase I trial of depsipeptide (FR901228) in patients with advanced cancer. J Exp. Ther. Oncol. 2002; 2: 325–332, [INFOTRIEVE], [CSA], [CROSSREF]
- Piekarz R. L., Frye R., Turner M., Wright J., et al. Responses and molecualr markers in patients with peripheral T cell lymphoma treated on a phase II trial of depsipeptide. ASCO 2005, FK 228[CSA]
- Kelly W. K., O'Connor O. A., Krug L. M., Chiao J. H., Heaney M., et al. Phase I. study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J. Clin. Oncol. 2005; 23: 3923–3931, [INFOTRIEVE], [CSA], [CROSSREF]
- Duvic M., Talpur R., Zhang C., Goy A., Richon V., Frankel S. R. Phase II trial of oral suberoylanilide hydroxamic acid for cutaneous T cell lymphoma unresponse to conventional therapy. ASCO 2005, [CSA]
- Ryan Q. C., Headlee D., Acharya M., Sparreboom A., Trepel J. B., et al. Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J. Clin. Oncol. 2005; 23: 3912–3922, [INFOTRIEVE], [CSA], [CROSSREF]
- Steele N., Vidal L., Plumb J., Attard G., Rasmussen A., et al. A phase I pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor PXD101 in patients with advanced solid tumors. Am. Soc. Clin. Oncol. 2005; 23, [CSA]
- Cameron E. E., Bachman K. E., Myohanen S., Herman J. G., Baylin S. B. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat. Genet. 1999; 21: 103–107, [INFOTRIEVE], [CSA], [CROSSREF]
- Zhu W. G., Lakshmanan R. R., Beal M. D., Otterson G. A. DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors. Cancer Res. 2001; 61: 1327–1333, [INFOTRIEVE], [CSA]
- Kim M. S., Blake M., Baek J. H., Kohlhagen G., Pommier Y., Carrier F. Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res. 2003; 63: 7291–7300, [INFOTRIEVE], [CSA]
- Chobanian N. H., Greenberg V. L., Gass J. M., Desimone C. P., Van Nagell J. R., Zimmer S. G. Histone deacetylase inhibitors enhance paclitaxel-induced cell death in ovarian cancer cell lines independent of p53 status. Anticancer Res. 2004; 24: 539–545, [INFOTRIEVE], [CSA]
- Bevins R. L., Zimmer S. G. It's about time: scheduling alters effect of histone deacetylase inhibitors on camptothecin-treated cells. Cancer Res. 2005; 65: 6957–6966, [INFOTRIEVE], [CSA], [CROSSREF]
- Rundall B. K., Denlinger C. E., Jones D. R. Suberoylanilide hydroxamic acid combined with gemcitabine enhances apoptosis in non-small cell lung cancer. Surgery 2005; 138: 360–367, [INFOTRIEVE], [CSA], [CROSSREF]
- Rosato R. R., Almenara J. A., Dai Y., Grant S. Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells. Mol. Cancer Ther. 2003; 2: 1273–1284, [INFOTRIEVE], [CSA]
- Maggio S. C., Rosato R. R., Kramer L. B., Dai Y., Rahmani M., et al. The histone deacetylase inhibitor MS-275 interacts synergistically with fludarabine to induce apoptosis in human leukemia cells. Cancer Res. 2004; 64: 2590–2600, [INFOTRIEVE], [CSA], [CROSSREF]
- Fuino L., Bali P., Wittmann S., Donapaty S., Guo F., et al. Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B. Mol. Cancer Ther. 2003; 2: 971–984, [INFOTRIEVE], [CSA]
- Chinnaiyan P., Vallabhaneni G., Armstrong E., Huang S. M., Harari P. M. Modulation of radiation response by histone deacetylase inhibition. Int. J. Radiat. Oncol. Biol. Phys. 2005; 62: 223–229, [INFOTRIEVE], [CSA], [CROSSREF]
- Camphausen K., Scott T., Sproull M., Tofilon P. J. Enhancement of xenograft tumor radiosensitivity by the histone deacetylase inhibitor MS-275 and correlation with histone hyperacetylation. Clin. Cancer Res. 2004; 10: 6066–6071, [INFOTRIEVE], [CSA], [CROSSREF]
- Zhang Y., Adachi M., Zhao X., Kawamura R., Imai K. Histone deacetylase inhibitors FK228, N-(2-aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)amino-methyl]benzamide and m-carboxycinnamic acid bis-hydroxamide augment radiation-induced cell death in gastrointestinal adenocarcinoma cells. Int. J. Cancer 2004; 110: 301–308, [INFOTRIEVE], [CSA], [CROSSREF]
- Zhang Y., Jung M., Dritschilo A., Jung M. Enhancement of radiation sensitivity of human squamous carcinoma cells by histone deacetylase inhibitors. Radiat. Res. 2004; 161: 667–674, [INFOTRIEVE], [CSA], [CROSSREF]